Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aflibercept plus modified FOLFOX6 as first-line treatment in metastatic colorectal cancer
2008-004178-41Phase 2Completed
- Sponsor
- Sanofi
- Start
- Sep 2008
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of aflibercept in metastatic colon cancer (mCRC) (2 arms), sponsored by Sanofi. Primary endpoint: Progression-free survival rate at 12 months. Started Sep 2008; status: completed.
02
Drugs
aflibercept
03
Conditions
metastatic colon cancer (mCRC)
Beyond the preview
Go deeper on 2008-004178-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-004178-41.